Fusion Moving FAST To Test FloSeal Feasibility In 30-Patient IDE Study
This article was originally published in The Gray Sheet
Executive Summary
Patient enrollment has begun at two sites in a randomized trial of the FloSeal Femoral Arteriotomy Sealing Technology (FAST) device, which is being developed by Fusion Medical for sealing femoral artery punctures created for diagnostic or therapeutic catheterization procedures.
You may also be interested in...
Fusion Looking To Enter Cranial Surgery Sealant Market With Proceed Gel
Fusion Medical sees a $35 mil. market opportunity for the cranial indication of the firm's Proceed hemostatic sealant, based on a projected per-kit price of $140 and more than 240,000 cranial procedures performed worldwide annually.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.